4basebio UK Societas (4BB) AI Stock Analysis

• Market Cap: £112.27M
• Dividend Yield: N/A
• Average Volume (3M): 1.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.04
• Revenue Growth: 84.39%
• EPS Growth: -41.02%
• Country: UK
• Employees: 101
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.52
• Shares Outstanding: 15,538,518
• 10 Day Avg. Volume: 1,335
• 30 Day Avg. Volume: 1,205
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £9.50
• Price Target Upside: -98.69% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: 9.50p ▼(-98.69% Downside)

4basebio UK Societas's overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. The bearish technical indicators further weigh on the score. However, recent positive corporate events suggest potential for future improvements.

4basebio UK Societas Business Overview & Revenue Model

Company Description

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.

How the Company Makes Money

4basebio UK Societas generates revenue primarily through the sale of its synthetic DNA products to pharmaceutical companies, research institutions, and biotechnology firms engaged in the development of gene therapies and vaccines. The company also enters into strategic partnerships and collaborations with other industry players to enhance its research and development capabilities and expand its market reach. Additionally, 4BB may receive licensing fees and royalties from the commercialization of products developed using its proprietary technologies.

4basebio UK Societas Financial Statement Overview

Summary

4basebio UK Societas faces significant financial challenges with continuous losses and negative cash flows. Despite some revenue growth and improved equity position, the persistent negative profit margins and cash flow inefficiencies are concerning.

Income Statement

4basebio UK Societas has shown some revenue growth, with a notable increase from 2023 to 2024. However, the company faces persistent losses, with a negative net profit margin and EBIT margin indicating ongoing profitability challenges. The gross profit margin is relatively healthy but overshadowed by high operating losses.

Balance Sheet

The company maintains a strong equity position with a positive equity ratio. However, the debt-to-equity ratio indicates a moderate level of leverage, which can be a risk for financial stability. The consistent increase in stockholders' equity from negative in 2023 to positive in 2024 is a positive sign of improving financial structure.

Cash Flow

The cash flow situation is concerning, with negative operating and free cash flows. Although there was a significant increase in financing cash flow in 2024, it primarily reflects external funding rather than strong operational performance. The negative free cash flow to net income ratio indicates inefficiency in converting income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	933.00K	506.00K	268.00K	338.00K	462.00K
Gross Profit	630.00K	340.00K	239.00K	269.00K	274.00K
EBITDA	-10.97M	-7.34M	-5.41M	-3.21M	-346.00K
Net Income	-12.33M	-7.67M	-5.15M	-3.23M	-719.00K
Balance Sheet
Total Assets	44.73M	11.92M	11.69M	14.70M	17.81M
Cash, Cash Equivalents and Short-Term Investments	34.60M	3.07M	4.35M	9.59M	15.00M
Total Debt	15.22M	10.46M	3.35M	1.76M	1.72M
Total Liabilities	18.35M	12.41M	4.57M	3.01M	2.35M
Stockholders Equity	26.38M	-492.00K	7.12M	11.70M	15.46M
Cash Flow
Free Cash Flow	-12.31M	-7.67M	-6.64M	-4.25M	-1.87M
Operating Cash Flow	-10.74M	-6.18M	-4.70M	-2.74M	-1.02M
Investing Cash Flow	-1.57M	-1.49M	-1.94M	-1.51M	1.45M
Financing Cash Flow	43.87M	6.42M	1.24M	-467.00K	14.43M

4basebio UK Societas Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 725.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:4BB, the sentiment is Negative. The current price of 725 is below the 20-day moving average (MA) of 831.25, below the 50-day MA of 896.50, and below the 200-day MA of 1069.08, indicating a bearish trend. The MACD of -46.02 indicates Positive momentum. The RSI at 7.02 is Positive, neither overbought nor oversold. The STOCH value of 14.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:4BB.

4basebio UK Societas Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	78 Outperform	130.62M	16.63	―	6.28%	0.49%	-9.52%
OXB	65 Neutral	699.46M	-16.39	-75.71%	―	55.44%	75.77%
PRTC	56 Neutral	306.46M	8.78	12.90%	―	1231.50%	―
ONT	51 Neutral	1.49B	-9.78	-24.93%	―	22.03%	20.01%
SCLP	46 Neutral	103.78M	-7.94	―	―	―	-85.29%
4BB	39 Underperform	£112.27M	―	-95.28%	―	84.39%	-41.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

4basebio UK Societas Corporate Events

4basebio Appoints Dr. Manja Boerman as Executive Chair Amid Board Changes

4basebio PLC announced the appointment of Dr. Manja Hermina Elisabeth Maria Boerman as Executive Chair of the Company, following an investment by Fort Aggregator LP, a Patient Square Capital platform. This appointment marks a significant board change, with Dr. Boerman bringing over 20 years of biopharmaceutical leadership experience to the role. The change in leadership is expected to support 4basebio’s ambition to accelerate commercial growth and enhance its platform, positioning the company as a preferred partner for high-quality synthetic DNA solutions.

4basebio UK Societas Announces Change in Voting Rights

4basebio UK Societas, a UK-based company, has announced a change in the breakdown of its voting rights. DELPHI Unternehmensberatung Aktiengesellschaft, based in Heidelberg, Germany, has adjusted its holdings, resulting in a slight decrease in its voting rights from 33.013180% to 32.985507%. This change signifies a minor shift in shareholder influence within the company, which may impact future decision-making processes.

4basebio Announces Change in Voting Rights Structure

4basebio UK Societas, a UK-based company, has announced a change in the breakdown of its voting rights. Wilhelm K. T. Zours, a major shareholder, now holds 32.985508% of the voting rights, slightly down from a previous position of 33.013179%. This adjustment in voting rights reflects a minor shift in shareholder influence, potentially impacting future company decisions and strategies.

4basebio PLC Announces AGM Results with Key Resolutions Amended

4basebio PLC announced the results of its Annual General Meeting, where most resolutions were passed, except for Resolutions 14 to 16, which were withdrawn for amendments and will be reintroduced later. This decision reflects the company’s ongoing efforts to refine its strategic direction and maintain its position in the biotechnology industry, potentially impacting stakeholders by ensuring alignment with evolving market and regulatory demands.

4basebio PLC Announces Exercise of Options and Share Issuance

4basebio PLC has announced the exercise of EMI options by two employees, resulting in the issuance of 13,000 new ordinary shares at an exercise price of £1.18 per share, raising £15,340 in total. These shares are set to be admitted to trading on AIM, with the total number of ordinary shares in issue rising to 15,509,393. This development is significant for shareholders as it impacts the total voting rights and may require them to notify changes in their shareholding under the Financial Conduct Authority’s rules.

4basebio UK Societas Announces Change in Major Holdings

4basebio UK Societas, a UK-based company, has announced a change in its major holdings. Wilhelm K. T. Zours has increased his voting rights in the company to 33.013179% from a previous 32.764383%, indicating a significant stake in the company. This change in holdings reflects an acquisition or disposal of voting rights, which may influence the company’s strategic decisions and impact stakeholders.

DELPHI Unternehmensberatung Increases Stake in 4basebio

4basebio UK Societas, a UK-based company, has announced a change in its major holdings. DELPHI Unternehmensberatung Aktiengesellschaft, based in Heidelberg, Germany, has increased its voting rights in 4basebio to 33.01% from a previous 32.76%. This acquisition of voting rights indicates a strategic move by DELPHI Unternehmensberatung to strengthen its influence within the company, potentially impacting 4basebio’s future decisions and strategies.

4basebio PLC Reports Strong 2024 Growth and Strategic Advancements

4basebio PLC reported significant growth in 2024, doubling its DNA sales revenue and securing a £40 million equity investment to support its expansion plans. The company achieved several milestones, including supplying synthetic DNA for vaccine trials, obtaining a GMP manufacturing license, and forming a Strategic Advisory Board. These developments position 4basebio as a leader in the synthetic DNA market, with expectations of continued revenue growth and innovation in 2025.